JNT-517 is under clinical development by Jnana Therapeutics and currently in Phase II for Phenylketonuria (PKU). According to GlobalData, Phase II drugs for Phenylketonuria (PKU) have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how JNT-517’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JNT-517 overview
JNT-517 is under development for the treatment of phenylketonuria. It is administered by oral route formulated as suspension. The therapeutic candidate acts by targeting SLC6A19 and developed based on reactive affinity probe interaction discovery (RAPID) platform and high-throughput, screening-enabled chemoproteomics platform.
Jnana Therapeutics overview
Jnana Therapeutics (Jnana) a of subsidiary Otsuka Pharmaceutical Co., Ltd is a biotechnology company. is a clinical-stage biotechnology company leveraging its next-generation RAPID chemoproteomics platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases. Its pipeline products include JNT-517, a cryptic site allosteric inhibitor for treating phenylketonuria, drugs targeting STING pathway and transcription factor inhibitor for treating immune mediated diseases. It also serves in the therapeutic areas like cancer and neurological diseases. The company works in collaboration with Roche and Neurocrine Biosciences. Jnana is headquartered in Boston, Massachusetts, the US.
For a complete picture of JNT-517’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
